Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05830968 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne
A NA study of Inflammatory Acne Vulgaris, sponsored by InMode MD.
- Recruiting
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT05830968: Recruiting NA study of Inflammatory Acne Vulgaris, sponsored by InMode MD.
NCT05830968 is a NA study of Inflammatory Acne Vulgaris that is actively recruiting participants, run by InMode MD. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05830968, a NA study of Inflammatory Acne Vulgaris, is actively recruiting participants, sponsored by InMode MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris
Conditions Studied
Interventions
- DEVICE Morpheus8 Applicator Radiofrequency device
Study Locations (4)
Arizona
- Avant Dermatology Aesthetics - Oro Valley
Colorado
- AboutSkin Research, LLC - Greenwood Village
New York
- UnionDerm - New York
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2026-05-01 |
| Phase | NA |
What NCT05830968 shows while recruiting
NCT05830968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Inflammatory Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Morpheus8 Applicator Radiofrequency device is the first listed.
NCT05830968 reports a single indexed study location in Arizona, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT05830968 about?
NCT05830968 is a clinical study titled "Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne". The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris
What is the current status of trial NCT05830968?
This trial is currently recruiting. It is a NA study. The enrollment target is 42 participants. The study started on 2023-05-01. Estimated completion is 2026-05-01.
What conditions does trial NCT05830968 study?
This clinical trial studies the following conditions: Inflammatory Acne Vulgaris.
What interventions are being tested in trial NCT05830968?
The interventions under investigation include: Morpheus8 Applicator Radiofrequency device (DEVICE).
Who is sponsoring clinical trial NCT05830968?
This trial is sponsored by InMode MD, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05830968 being conducted?
This trial has 4 study locations across Arizona, Colorado, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05830968's enrollment target sits among peer trials
42 1436th of 2000 higher than 555 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI